The UK and US have reached a key trade agreement that will preserve zero tariffs on British pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the public health system. This commitment guarantees that tariffs on these vital exports will stay at nothing for a period of three years.
This agreement comes after recent warnings to hike duties on branded drug products, with potential rates discussed reaching double the cost.
"This arrangement with the Britain strengthens the global environment for new treatments and brings much-needed fairness to U.S.–U.K. drug exports," a statement said.
Commercial Importance
Drugs constitute one of the UK's largest goods shipped to the America, which is easily the largest market for major UK drugmakers.
Export figures indicate that in the year leading up to the third quarter, the UK shipped pharmaceutical products totaling £11.1bn to the US. This value accounted for a significant portion of total UK exports in that timeframe.
"This agreement protects jobs, increases investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Specific NHS Changes
The pact entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to raise total public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates exceeded 20%.
Broader Context
This agreement follows a long-running dispute between the drug companies and the ministers over medicine costs and approval rates.
The disagreement were heightened by arguments that American customers were paying significantly more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the previous ten-year period.
